Abstract
End-stage liver disease is marked by portal hypertension, systemic elevations in ammonia, and development of hepatocellular carcinoma (HCC). While these clinical consequences of cirrhosis are well described, it remains poorly understood whether hepatic insufficiency and the accompanying elevations in ammonia contribute to HCC carcinogenesis. Using preclinical models, we discovered that ammonia entered the cell through the transporter SLC4A11 and served as a nitrogen source for amino acid and nucleotide biosynthesis. Elevated ammonia promoted cancer stem cell properties in vitro and tumor initiation in vivo. Enhancing ammonia clearance reduced HCC stemness and tumor growth. In patients, elevations in serum ammonia were associated with an increased incidence of HCC. Taken together, this study forms the foundation for clinical investigations using ammonia-lowering agents as potential therapies to mitigate HCC incidence and aggressiveness.
Authors
Ameer L. Elaimy, Marwa O. El-Derany, Jadyn James, Zhuwen Wang, Ashley N. Pearson, Erin A. Holcomb, Amanda K. Huber, Miguel Gijón, Hannah N. Bell, Viraj R. Sanghvi, Timothy L. Frankel, Grace L. Su, Elliot B. Tapper, Andrew W. Tai, Nithya Ramnath, Christopher P. Centonze, Irina Dobrosotskaya, Julie A. Moeller, Alex K. Bryant, David A. Elliott, Enid Choi, Joseph R. Evans, Kyle C. Cuneo, Thomas J. Fitzgerald, Daniel R. Wahl, Meredith A. Morgan, Daniel T. Chang, Max S. Wicha, Theodore S. Lawrence, Yatrik M. Shah, Michael D. Green
Graphical abstract
